Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population

Por Engel-Nitz, Nicole M, Alemayehu, Berhanu, Parry, David, Nathan, Faith
Publicado em 2011

Pain in castration-resistant prostate cancer with bone metastases: a qualitative study

Por Gater, Adam, Abetz-Webb, Linda, Battersby, Clare, Parasuraman, Bhash, McIntosh, Stuart, Nathan, Faith, Piault, Elisabeth C
Publicado em 2011

Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Ca...

Por Yu, Evan Y., Miller, Kurt, Nelson, Joel, Gleave, Martin, Fizazi, Karim, Moul, Judd W., Nathan, Faith E., Higano, Celestia S.
Publicado em 2012

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurren...

Por Hellmann, Matthew, Ramalingam, Suresh, Reck, Martin, O'Byrne, Ken, Paz-Ares, Luis, Harbison, Christopher T, Bhagavatheeswaran, Prabhu, Nathan, Faith, Brahmer, Julie
Publicado no J Immunother Cancer (2015)